Gut and Liver

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting

  • Gayam, Vijay (Department of Medicine and Gastroenterology, Interfaith Medical Center) ;
  • Hossain, Muhammad Rajib (Department of Medicine and Gastroenterology, Interfaith Medical Center) ;
  • Khalid, Mazin (Department of Medicine and Gastroenterology, Interfaith Medical Center) ;
  • Chakaraborty, Sandipan (Department of Medicine and Gastroenterology, Interfaith Medical Center) ;
  • Mukhtar, Osama (Department of Medicine and Gastroenterology, Interfaith Medical Center) ;
  • Dahal, Sumit (Department of Medicine and Gastroenterology, Interfaith Medical Center) ;
  • Mandal, Amrendra Kumar (Department of Medicine and Gastroenterology, Interfaith Medical Center) ;
  • Gill, Arshpal (Department of Medicine and Gastroenterology, Interfaith Medical Center) ;
  • Garlapati, Pavani (Department of Medicine and Gastroenterology, Interfaith Medical Center) ;
  • Ramakrishnaiah, Sreedevi (Department of Medicine and Gastroenterology, Interfaith Medical Center) ;
  • Mowyad, Khalid (Department of Medicine, Detroit Medical Center, Wayne State University) ;
  • Sherigar, Jagannath (Division of Gastroenterology and Hepatology, Department of Medicine, New York-Presbyterian Brooklyn Methodist Hospital) ;
  • Mansour, Mohammed (Department of Medicine and Gastroenterology, Interfaith Medical Center) ;
  • Mohanty, Smruti (Division of Gastroenterology and Hepatology, Department of Medicine, New York-Presbyterian Brooklyn Methodist Hospital)
  • Received : 2017.12.29
  • Accepted : 2018.03.26
  • Published : 2018.11.15
⟨ Previous Next ⟩

Abstract

Background/Aims: Limited data exist comparing the safety and efficacy of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) monoinfected and HCV/human immunodeficiency virus (HIV) coinfected patients in the real-world clinic practice setting. Methods: All HCV monoinfected and HCV/HIV coinfected patients treated with DAAs between January 2014 and October 2017 in community clinic settings were retrospectively analyzed. Pretreatment baseline patient characteristics, treatment efficacy, factors affecting sustained virologic response at 12 weeks (SVR12) after treatment, and adverse reactions were compared between the groups. Results: A total of 327 patients were included in the study, of which 253 were HCV monoinfected, and 74 were HCV/HIV coinfected. There was a statistically significant difference observed in SVR12 when comparing HCV monoinfection and HCV/HIV coinfection (94% and 84%, respectively, p=0.005). However, there were no significant factors identified as a predictor of a reduced response. The most common adverse effect was fatigue (27%). No significant drug interaction was observed between DAA and antiretroviral therapy. None of the patients discontinued the treatment due to adverse events. Conclusions: In a real-world setting, DAA regimens have lower SVR12 in HCV/HIV coinfection than in HCV monoinfection. Further studies involving a higher number of HCV/HIV coinfected patients are needed to identify real predictors of a reduced response.

Keywords

References

  1. Balogun MA, Ramsay ME, Hesketh LM, et al. The prevalence of hepatitis C in England and Wales. J Infect 2002;45:219-226. https://doi.org/10.1053/jinf.2002.1059
  2. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000;356:291-296. https://doi.org/10.1016/S0140-6736(00)02504-6
  3. Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013;158:658-666. https://doi.org/10.7326/0003-4819-158-9-201305070-00604
  4. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002;100:1584-1589.
  5. Vogel M, Page E, Boesecke C, et al. Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals. Clin Infect Dis 2012;54:556-559. https://doi.org/10.1093/cid/cir854
  6. Soriano V, Labarga P, Ruiz-Sancho A, Garcia-Samaniego J, Barreiro P. Regression of liver fibrosis in hepatitis C virus/HIV-coinfected patients after treatment with pegylated interferon plus ribavirin. AIDS 2006;20:2225-2227. https://doi.org/10.1097/01.aids.0000247583.38943.95
  7. Hepatitis C Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Is response to anti-hepatitis C virus treatment predictive of mortality in hepatitis C virus/HIV-positive patients? AIDS 2017;31:661-668. https://doi.org/10.1097/QAD.0000000000001378
  8. Berenguer J, Zamora FX, Carrero A, et al. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. J Acquir Immune Defic Syndr 2014;66:280-287. https://doi.org/10.1097/QAI.0000000000000156
  9. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007;196:670-676. https://doi.org/10.1086/520092
  10. Martin TC, Martin NK, Hickman M, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 2013;27:2551-2557. https://doi.org/10.1097/QAD.0b013e32836381cc
  11. Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 2013;56:718-726. https://doi.org/10.1093/cid/cis968
  12. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450. https://doi.org/10.1056/NEJMoa040842
  13. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 2014;312:353-361. https://doi.org/10.1001/jama.2014.7734
  14. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015;313:1232-1239. https://doi.org/10.1001/jama.2015.1373
  15. Saeed S, Strumpf EC, Walmsley SL, et al. How generalizable are the results from trials of direct antiviral agents to people coinfected with HIV/HCV in the real world? Clin Infect Dis 2016;62:919-926. https://doi.org/10.1093/cid/civ1222
  16. Bhattacharya D, Belperio PS, Shahoumian TA, et al. Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Clin Infect Dis 2017;64:1711-1720. https://doi.org/10.1093/cid/cix111
  17. Khatri A, Dutta S, Wang H, et al. Evaluation of drug-drug interactions between hepatitis C antiviral agents ombitasvir, paritaprevir/ritonavir, and dasabuvir and HIV-1 protease inhibitors. Clin Infect Dis 2016;62:972-979. https://doi.org/10.1093/cid/civ1213
  18. Wyles D, Saag M, Viani RM, et al. TURQUOISE-I Part 1b: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for hepatitis C virus infection in HIV-1 coinfected patients on darunavir. J Infect Dis 2017;215:599-605. https://doi.org/10.1093/infdis/jiw597
  19. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015;63:199-236. https://doi.org/10.1016/j.jhep.2015.03.025
  20. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-954. https://doi.org/10.1002/hep.27950
  21. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206. https://doi.org/10.1056/NEJMoa1010494
  22. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416. https://doi.org/10.1056/NEJMoa1012912
  23. Milazzo L, Lai A, Calvi E, et al. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med 2017;18:284-291. https://doi.org/10.1111/hiv.12429
  24. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898. https://doi.org/10.1056/NEJMoa1402454
  25. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493. https://doi.org/10.1056/NEJMoa1316366
  26. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-1992. https://doi.org/10.1056/NEJMoa1402338
  27. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-1765. https://doi.org/10.1016/S0140-6736(14)61036-9
  28. Rivero-Juarez A, Mira JA, Camacho A, et al. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. Infection 2013;41:21-26. https://doi.org/10.1007/s15010-012-0352-4
  29. Rallon NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010;24:F23-F29. https://doi.org/10.1097/QAD.0b013e3283391d6d
  30. Bruno G, Saracino A, Scudeller L, et al. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Int J Infect Dis 2017;62:64-71. https://doi.org/10.1016/j.ijid.2017.07.001
  31. Werner CR, Schwarz JM, Egetemeyr DP, et al. Second-generation direct-acting-antiviral hepatitis C virus treatment: efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016;22:8050-8059. https://doi.org/10.3748/wjg.v22.i35.8050
  32. Neukam K, Morano-Amado LE, Rivero-Juarez A, et al. HIVcoinfected patients respond worse to direct-acting antiviralbased therapy against chronic hepatitis C in real life than HCVmonoinfected individuals: a prospective cohort study. HIV Clin Trials 2017;18:126-134. https://doi.org/10.1080/15284336.2017.1330801
  33. Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV inpatients coinfected with HIV-1. N Engl J Med 2015;373:705-713. https://doi.org/10.1056/NEJMoa1501315
  34. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatmentnaive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-523. https://doi.org/10.1016/S0140-6736(13)62121-2
  35. Jansen JW, Powderly GM, Linneman TW. Identification of predictors for treatment failure in hepatitis C virus patients treated with ledipasvir and sofosbuvir. Ann Pharmacother 2017;51:543-547. https://doi.org/10.1177/1060028017693348
  36. Cavalcante LN, Lyra AC. Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol 2015;7:1617-1631. https://doi.org/10.4254/wjh.v7.i12.1617
  37. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 2016;64:360-369. https://doi.org/10.1002/hep.28422
  38. Marot A, Trepo E, Doerig C, Schoepfer A, Moreno C, Deltenre P. Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding. Liver Int 2017;37:707-716. https://doi.org/10.1111/liv.13318
  39. Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 2016;63:1430-1441. https://doi.org/10.1002/hep.28473

Cited by

  1. Efficacy of Direct-Acting Antivirals in Patients with Hepatitis C Virus/Human Immunodeficiency Virus Coinfection: A Gap between Clinical Trial and Real Practice vol.12, pp.6, 2018, https://doi.org/10.5009/gnl18418
  2. Efficacy of Direct‐Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States vol.68, pp.2, 2018, https://doi.org/10.1111/jgs.16206
  3. Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study vol.32, pp.6, 2018, https://doi.org/10.1080/09540121.2019.1645808
  4. Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co‐infection: systematic review and network meta‐analysis vol.35, pp.9, 2020, https://doi.org/10.1111/jgh.15051
  5. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea vol.36, pp.46, 2021, https://doi.org/10.3346/jkms.2021.36.e308
  6. Barriers to hepatitis C direct‐acting antiviral therapy among HIV/hepatitis C virus‐coinfected persons vol.36, pp.4, 2018, https://doi.org/10.1111/jgh.15228